AVDL

Avadel Pharmaceuticals

13.15 USD
-3.15
19.33%
At close Nov 12, 4:00 PM EST
After hours
13.11
-0.04
0.30%
1 day
-19.33%
5 days
-14.11%
1 month
-0.15%
3 months
-17.81%
6 months
-21.77%
Year to date
-7.91%
1 year
22.44%
5 years
163.00%
10 years
9.04%
 

About: Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. It identifies, develops, and commercializes branded pharmaceutical products including controlled-release therapeutic products based on its proprietary drug delivery technologies in the United States. The company is engaged in development of differentiated drug products for administration in various forms such as capsules, tablets, injectables etc. Its commercialized product LUMRYZ is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or EDS in adults with narcolepsy.

Employees: 154

0
Funds holding %
of 6,759 funds
0
Analysts bullish %
of 9 analysts

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

188% more call options, than puts

Call options by funds: $31.3M | Put options by funds: $10.9M

123% more first-time investments, than exits

New positions opened: 49 | Existing positions closed: 22

21% more funds holding

Funds holding: 126 [Q1] → 153 (+27) [Q2]

13% more repeat investments, than reductions

Existing positions increased: 43 | Existing positions reduced: 38

12% more capital invested

Capital invested by funds: $1.22B [Q1] → $1.37B (+$151M) [Q2]

2.01% less ownership

Funds ownership: 79.6% [Q1] → 77.59% (-2.01%) [Q2]

20% less funds holding in top 10

Funds holding in top 10: 10 [Q1] → 8 (-2) [Q2]

Research analyst outlook

9 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$22
67%
upside
Avg. target
$25
87%
upside
High target
$30
128%
upside

9 analyst ratings

positive
100%
neutral
0%
negative
0%
Needham
Ami Fadia
66% 1-year accuracy
96 / 146 met price target
67%upside
$22
Buy
Reiterated
12 Nov 2024
HC Wainwright & Co.
Oren Livnat
55% 1-year accuracy
22 / 40 met price target
105%upside
$27
Buy
Reiterated
31 Oct 2024
Oppenheimer
Francois Brisebois
71% 1-year accuracy
24 / 34 met price target
128%upside
$30
Outperform
Maintained
31 Oct 2024
Needham
Ami Fadia
66% 1-year accuracy
96 / 146 met price target
67%upside
$22
Buy
Reiterated
31 Oct 2024
HC Wainwright & Co.
Oren Livnat
55% 1-year accuracy
22 / 40 met price target
105%upside
$27
Buy
Reiterated
21 Oct 2024

Financial journalist opinion

Based on 5 articles about AVDL published over the past 30 days

Charts implemented using Lightweight Charts™